BR112021018039A2 - Rna terapêutico para câncer de próstata - Google Patents

Rna terapêutico para câncer de próstata

Info

Publication number
BR112021018039A2
BR112021018039A2 BR112021018039A BR112021018039A BR112021018039A2 BR 112021018039 A2 BR112021018039 A2 BR 112021018039A2 BR 112021018039 A BR112021018039 A BR 112021018039A BR 112021018039 A BR112021018039 A BR 112021018039A BR 112021018039 A2 BR112021018039 A2 BR 112021018039A2
Authority
BR
Brazil
Prior art keywords
immunogenic
amino acid
variant
acid sequence
immunogenic variant
Prior art date
Application number
BR112021018039A
Other languages
English (en)
Inventor
Carina Walter
David Weber
BAREA ROLDAN Diana
Elif Diken
Martin Suchan
Ruprecht Kuner
GANGI MAURICI Stefania
Ugur Sahin
Original Assignee
BioNTech SE
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical BioNTech SE
Publication of BR112021018039A2 publication Critical patent/BR112021018039A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A61K39/00116—Serine proteases, e.g. kallikrein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

rna terapêutico para câncer de próstata. são divulgados aqui composições, usos e métodos para tratamento de cânceres de próstata. em um aspecto, é divulgada aqui uma composição ou uma preparação médica que compreende pelo menos um rna, em que pelo menos um rna codifica as sequências de aminoácidos a seguir: (i) uma sequência de aminoácidos que compreende kallikrein-2 (klk2), uma variante imunogênica da mesma ou um fragmento imunogênico da klk2 ou a variante imunogênica do mesmo; (ii) uma sequência de aminoácidos que compreende antígeno específico da próstata (psa), uma variante imunogênica do mesmo ou um fragmento imunogênico do psa ou a variante imunogênica do mesmo; (iii) uma sequência de aminoácidos que compreende fosfatase ácida prostática (pap), uma variante imunogênica da mesma ou um fragmento imunogênico da pap ou a variante imunogênica do mesmo; (iv) uma sequência de aminoácidos que compreende a homeobox b13 (hoxb13), uma variante imunogênica da mesma ou um fragmento imunogênico da hoxb13 ou a variante imunogênica do mesmo; e (v) uma sequência de aminoácidos que compreende nk3 homeobox 1 (nkx3-1), uma variante imunogênica da mesma ou um fragmento imunogênico da nkx3-1 ou a variante imunogênica do mesmo.
BR112021018039A 2019-03-12 2020-03-11 Rna terapêutico para câncer de próstata BR112021018039A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019056185 2019-03-12
PCT/EP2020/056476 WO2020182869A1 (en) 2019-03-12 2020-03-11 Therapeutic rna for prostate cancer

Publications (1)

Publication Number Publication Date
BR112021018039A2 true BR112021018039A2 (pt) 2021-11-23

Family

ID=69743256

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018039A BR112021018039A2 (pt) 2019-03-12 2020-03-11 Rna terapêutico para câncer de próstata

Country Status (17)

Country Link
US (1) US20230114808A1 (pt)
EP (1) EP3917562A1 (pt)
JP (1) JP2022525103A (pt)
KR (1) KR20210138586A (pt)
CN (1) CN113710267A (pt)
AU (1) AU2020233995A1 (pt)
BR (1) BR112021018039A2 (pt)
CA (1) CA3132908A1 (pt)
CL (1) CL2021002359A1 (pt)
CO (1) CO2021011892A2 (pt)
CU (1) CU20210075A7 (pt)
IL (1) IL285961A (pt)
MA (1) MA54868A (pt)
MX (1) MX2021010862A (pt)
SG (1) SG11202108691TA (pt)
WO (1) WO2020182869A1 (pt)
ZA (1) ZA202106392B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112501201A (zh) * 2021-02-07 2021-03-16 无锡市人民医院 一种用于治疗非小细胞肺癌的rna疫苗及其构建方法
WO2023030635A1 (en) * 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
KR20230144421A (ko) * 2022-04-07 2023-10-16 엠큐렉스 주식회사 사스-코로나바이러스 2 감염증에 대한 rna 백신

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2015024664A1 (en) * 2013-08-21 2015-02-26 Curevac Gmbh Composition and vaccine for treating prostate cancer
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
US20190343942A1 (en) * 2016-04-22 2019-11-14 Curevac Ag Rna encoding a tumor antigen

Also Published As

Publication number Publication date
SG11202108691TA (en) 2021-09-29
CU20210075A7 (es) 2022-04-07
EP3917562A1 (en) 2021-12-08
CO2021011892A2 (es) 2022-01-28
KR20210138586A (ko) 2021-11-19
CA3132908A1 (en) 2020-09-17
CL2021002359A1 (es) 2022-04-08
IL285961A (en) 2021-10-31
ZA202106392B (en) 2023-06-28
MX2021010862A (es) 2021-10-22
AU2020233995A1 (en) 2021-09-23
CN113710267A (zh) 2021-11-26
MA54868A (fr) 2021-12-08
US20230114808A1 (en) 2023-04-13
JP2022525103A (ja) 2022-05-11
WO2020182869A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
BR112021018039A2 (pt) Rna terapêutico para câncer de próstata
HRP20210766T1 (hr) Imunoterapija na bazi indoleamin 2, 3-dioksigenaze
MX2019001920A (es) Arn la terapia contra el cancer.
NO20062876L (no) Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
DE60135005D1 (de) Verbindungen und methoden zur wt1-spezifischen immuntherapie
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR112018015238A2 (pt) conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição
DK1468014T3 (da) Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
BR0112542A (pt) Composições e métodos papa a terapia e a diagnose de câncer ovariano
DK1255537T3 (da) Farnesylproteintransferasehæmmere til behandling af brystcancer
CL2021002669A1 (es) (divisional de solicitud 3443-2018) tratamientos de cancer.
BR112021022106A2 (pt) Rna terapêutico para câncer de ovário
HUP0402656A2 (hu) Sejtterápiás eljárás tumorok kezelésére
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
WO2012079878A3 (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
BR112022009100A2 (pt) Peptídeos antigênicos para prevenção e tratamento de malignidade de células b
BRPI0308606B8 (pt) compostos derivados de hemiasterlina e composição farmacêutica compreendendo os mesmos
MX2021005400A (es) Terapia del cancer con celulas inmunitarias anti-ptk7.
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
DE60326001D1 (de) Sterile immunogene nicht-tumorigene tumorzell-zusammensetzungen und verfahren
MX2022005345A (es) Terapia de combinación para el tratamiento de cáncer cerebral.
ZA202110285B (en) Antibodies and methods of use
BR112022021956A2 (pt) Métodos, terapias e usos para o tratamento de câncer